Vitreous cavity haemorrhage post-vitrectomy for diabetic eye disease: The effect of perioperative anticoagulation and antiplatelet agents

Clinical and Experimental Ophthalmology

Volumn 39, Issue 9, 2011, Pages 878-884

  Fabinyi, David Ca ^a   O'Neill, Evelyn C ^b   Connell, Paul P ^a,b   Clark, J Ben ^a  

^a ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Anticoagulation; Antiplatelet agent; Diabetes; Vitrectomy; Vitreous haemorrhage

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ARTICLE; CILIARY DISK; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VITRECTOMY; VITREOUS HEMORRHAGE;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DIABETIC RETINOPATHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; REOPERATION; RETROSPECTIVE STUDIES; RISK FACTORS; VISUAL ACUITY; VITRECTOMY; VITREOUS HEMORRHAGE; YOUNG ADULT;

EID: 82955163237     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2011.02575.x     Document Type: Article

References (27)

1. Colwell JA. Aspirin therapy in diabetes. Diabetes Care 2004; 27 (Suppl. 1): S72-3.
2. Macrovascular Disease Expert Working Group. Prevention and Detection of Macrovascular Disease in Type 2 Diabetes. National Evidence Based Guidelines for the Management of Type 2 Diabetes Mellitus. Sydney: National Health Medical Research Council, 2001.
3. Albaladejo P, Samama CM. Patients under anti-platelet therapy. Best Pract Res Clin Anaesthesiol 2010; 24: 41-50.
4. Harder S, Klinkhardt U, Alvarez JM. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2004; 43: 963-81.
5. Batra R, Maino A, Ch'ng SW, Marsh IB. Perioperative management of anticoagulated patients having cataract surgery: national audit of current practice of members of the Royal College of Ophthalmologists. J Cataract Refract Surg 2009; 35: 1815-20.
6. Konstantatos A. Anticoagulation and cataract surgery: a review of the current literature. Anaesth Intensive Care 2001; 29: 11-18.
7. Alwitry A, King AJ, Vernon SA. Anticoagulation therapy in glaucoma surgery. Graefes Arch Clin Exp Ophthalmol 2008; 246: 891-6.
8. McCormack P, Simcock PR, Tullo AB. Management of the anticoagulated patient for ophthalmic surgery. Eye (Lond) 1993; 7: 749-50.
9. Parkin B, Manners R. Aspirin and warfarin therapy in oculoplastic surgery. Br J Ophthalmol 2000; 84: 1426-7.
10. Dayani PN, Grand MG. Maintenance of warfarin anticoagulation for patients undergoing vitreoretinal surgery. Arch Ophthalmol 2006; 124: 1558-65.
11. Fu AD, McDonald HR, Williams DF etal. Anticoagulation with warfarin in vitreoretinal surgery. Retina 2007; 27: 290-5.
12. Blankenship GW. Management of vitreous cavity hemorrhage following pars plana vitrectomy for diabetic retinopathy. Ophthalmology 1986; 93: 39-44.
13. Lo WR, Kim SJ, Aaberg TM Sr etal. Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin). Retina 2009; 29: 926-31.
14. Novak MA, Rice TA, Michels RG, Auer C. Vitreous hemorrhage after vitrectomy for diabetic retinopathy. Ophthalmology 1984; 91: 1485-9.
15. Schachat AP, Oyakawa RT, Michels RG, Rice TA. Complications of vitreous surgery for diabetic retinopathy. II. Postoperative complications. Ophthalmology 1983; 90: 522-30.
16. Tolentino FI, Cajita VN, Gancayco T, Skates S. Vitreous hemorrhage after closed vitrectomy for proliferative diabetic retinopathy. Ophthalmology 1989; 96: 1495-500.
17. Yeh PT, Yang CM, Yang CH, Huang JS. Cryotherapy of the anterior retina and sclerotomy sites in diabetic vitrectomy to prevent recurrent vitreous hemorrhage: an ultrasound biomicroscopy study. Ophthalmology 2005; 112: 2095-102.
18. Holladay JT. Proper method for calculating average visual acuity. J Refract Surg 1997; 13: 388-91.
19. Dayani PN, Grand MG. Maintenance of warfarin anticoagulation for patients undergoing vitreoretinal surgery. Trans Am Ophthalmol Soc 2006; 104: 149-60.
20. Narendran N, Williamson TH. The effects of aspirin and warfarin therapy on haemorrhage in vitreoretinal surgery. Acta Ophthalmol Scand 2003; 81: 38-40.
21. Neely KA, Scroggs MW, McCuen BW 2nd. Peripheral retinal cryotherapy for postvitrectomy diabetic vitreous hemorrhage in phakic eyes. Am J Ophthalmol 1998; 126: 82-90.
22. Yang CM, Yeh PT, Yang CH. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology 2007; 114: 710-15.
23. Cheema RA, Mushtaq J, Cheema MA. Role of residual vitreous cortex removal in prevention of postoperative vitreous hemorrhage in diabetic vitrectomy. Int Ophthalmol 2010; 30: 137-42.
24. El-Batarny AM. Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy. Clin Ophthalmol 2008; 2: 709-16.
25. Yeoh J, Williams C, Allen P etal. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clin Experiment Ophthalmol 2008; 36: 449-54.
26. Yeh PT, Yang CM, Lin YC, Chen MS, Yang CH. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina 2009; 29: 768-74.
27. Cheema RA, Mushtaq J, Al-Khars W, Al-Askar E, Cheema MA. Role of intravitreal bevacizumab (Avastin) injected at the end of diabetic vitrectomy in preventing postoperative recurrent vitreous hemorrhage. Retina 2010; 30: 1646-50.